D 2 Antagonist Augmentation in Patients with a Partial Response to Atypical Antipsychotics

Lalonde P. Evaluating antipsychotic medications: Predictors of clinical effectiveness. Report of an expert review panel on efficacy and effectiveness. Can J Psychiatry 2003;48(Suppl 1):3S–12S.

Tandon R Jibson MD . Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28(suppl 1):9–26.

Taylor DM Young C Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: A case note review. J Clin Psychiatry 2003;64(1):30–4.

Beasley CM Tollefson G Tran P Satterlee W Sanger T Hamilton S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111–23.

Kapur S Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient. Biol Psychiatry 2001;50:873–83.

Jaffe AB Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12:41–8.

Miller AL Chiles JA Chiles JK Crismon ML Rush J Shon SP . The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999;60:10:649–57.

Gupta S Sonnenberg SJ Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998;10:113–5.

McCarthy RH Terkelsen KG . Risperidone augmentation of clozapine. Pharmacopsychiatry 1995;28(2):61–3.